Dataset Information

Diagnostic accuracy of pocket-sized ultrasound for aspiration pneumonia in elderly patients without heart failure: A prospective observational study.

ABSTRACT:

Aim

To investigate the diagnostic accuracy of pocket-sized ultrasound (PsUS) for aspiration pneumonia in elderly patients without heart failure.

Methods

This prospective observational study included patients with aspiration pneumonia. PsUS was performed in six areas (bilateral chest, four dorsal areas) by an independent examiner, blinded to the computed tomography (CT) results as a reference standard. Patients with heart failure were excluded.

Results

PsUS findings of 34 patients (median age, 87.5 years) and 204 areas were analyzed. Three or more B-lines (comet tail artifacts) were strongly suggestive (positive likelihood ratio [LR+] 17.302) of consolidation on CT (CT-consolidation, subpleural hypoechoic area with tissue-like echostructure) or pleural change on CT. Consolidation on US (US-consolidation) was suggestive of CT-consolidation or pleural changes on CT (LR+ 6.453). Pleural effusion on US was strongly suggestive (LR+ 10.989) of CT-consolidation or pleural change on CT. Absence of either three or more B-lines, US-consolidation, or US pleural effusion could not rule out CT-consolidation or pleural change on CT (negative likelihood ratio [LR-] 0.482-0.683). However, absence of all three findings could rule out abnormal CT findings (LR- 0.230). Chest radiograph findings proved difficult to confirm or exclude CT-consolidation or pleural changes on CT (LR+ 1.584, LR- 0.489); when combined with PsUS findings, LR- improved to 0.124.

Conclusions

Three or more B-lines or US-consolidation on PsUS in elderly patients with aspiration pneumonia without heart failure suggested CT-consolidation or pleural changes on CT. When both PsUS and chest radiograph findings were negative, CT-consolidation and pleural change could be excluded. Geriatr Gerontol Int 2021; 21: 1118-1124.

SUBMITTER: Yamanaka H

PROVIDER: S-EPMC9293111 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:ObjectiveFibrosis is the key prognostic factor in chronic liver disease patients. Liver surface nodularity (LSN) is the ultrasonographic sign with the highest accuracy to detect advanced liver fibrosis. The use of pocket-sized ultrasound devices (PUDs) has been assessed in several clinical settings but never as regards chronic liver disease (CLD) severity. Our study aimed at evaluating the feasibility, reproducibility, and diagnostic accuracy of PUD in LSN identification.MethodsWe enrolled all the consecutive adults referred for percutaneous liver biopsy. Two independent operators evaluated LSN by PUD; one sonographer used standard ultrasound (US). Transient elastography (TE) and liver biopsy were performed on all the patients. PUD reproducibility was evaluated by Cohen's k statistic. PUD, standard US, and TE results were compared with histology staging.ResultsA total of 104 consecutive patients (aged 54 ± 14 years) with mixed-etiology CLD were studied. Assessment by PUD was feasible in all the patients and showed very good inter-observer agreement with Cohen's k = 0.87 (95% CI 0.72-0.95). The diagnostic accuracy estimates for PUD in diagnosing compensated cirrhosis (F = 4) were 87.5% sensitivity, 76.8% specificity, positive likelihood ratio (LR) 3.78, and negative likelihood ratio (LR-) 0.16, while those for standard US and TE (> 12.5 kPa) were, respectively, 87.5% sensitivity, 72.6% specificity, LR+ 3.2, and LR- 0.17, and 87.5% sensitivity, 90.5% specificity, LR + 9.2, and LR- 0.13.ConclusionsPUD reproducibility in assessing LSN was excellent even with operators of different experience. PUD performed very well in excluding advanced CLD. PUD can be used as a first-line tool for screening patients to undergo more invasive techniques, thus shortening the time for clinical decision-making.Key points• PUD is highly reproducible in assessing the sign of liver surface nodularity. • PUD showed high diagnostic accuracy in excluding the presence of advanced chronic liver disease. • PUD can be used as a first-line tool for screening patients with CLD who should undergo more invasive techniques.